

Antibiotics resistance and mitigation strategies in healthcare settings: A scoping review

Authors

Bernard Okeah

Jaci Huws

Valerie Morrison

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background: According to the European Center for Disease Prevention and Control (ECDC), the EU records an estimated 3.2 million healthcare associated infections (HAIs) and an associated 37,000 deaths annually. A significant proportion of the HAIs burden is attributable to multi-drug resistant pathogens. Infectious diseases remain top on the list of the leading causes of death globally with multi-drug resistant microorganisms (MDROs) playing a significant role.

Aims: To assess the breadth of studies on antibiotics stewardship *C. diff* and *Klebsiella pneumoniae* in healthcare settings. To identify existing literature on the interventions for reducing healthcare associated *C. diff* and *Klebsiella pneumoniae* transmission.

Methods: This scoping review was undertaken and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) guidelines. The specific databases searched included MEDLINE, PubMed, Web of Science Core Collection, and CINAHL. The process for screening articles and data extraction was undertaken in duplicate by two reviewers. A narrative synthesis of the results is provided.

Results: The review included 34 studies (16 studies on *Clostridium difficile* and 18 articles focussed on *Klebsiella pneumoniae*). These interventions include Education, Surveillance/Screening, Consultations, Audits, Policies/Protocols, Environmental disinfection, Bundles, Isolation, and Notifications or alerts (ESCAPE-BIN). A study involving screening, alerts, staff education, and antimicrobial protocols recorded a 75% reduction in the use of targeted antimicrobials. The largest absolute reduction in antimicrobial use of 310 DDs/1000PDs was reported from an intervention that involved audits and feedback systems. The highest improvement (95%) in adherence was reported by an intervention involving the use of an infection prevention bundle and an environmental cleaning protocol.

Conclusion: Antimicrobial resistance represents a global threat requiring urgent measures to protect lives. Reducing the burden of AMR entails a host of multi-level approaches aimed at curbing transmission of the resistant pathogens, and optimizing the use of antibiotics.

Table of contents

Introduction	5
Surveillance and resistance patterns.....	7
Clostridium difficile.....	7
Klebsiella pneumoniae.....	7
Rationale.....	8
Research objectives.....	10
Methods	10
Research protocol	11
Eligibility criteria.....	11
Information sources	12
Literature search	13
Study selection.....	13
Data charting.....	13
Results collation, summary, and report compilation	14
Results	15
Selection of sources of evidence	15
Characteristics of selected studies.....	16
Synthesis of results	16
Discussion.....	26
Summary of evidence	26
Limitations.....	27
Conclusions	27
References	28
Appendix 1: Search strategy	47
a. MEDLINE search strategy.....	47
b. CINAHL Plus	47
c. Web of Science Core Collection	47
d. PubMed.....	48
Appendix 2: Data Extraction.....	49
a. Clostridium difficile.....	49
b. Klebsiella pneumoniae.....	53

List of tables

Table 1: Eligibility criteria.....	12
Table 2: MEDLINE search strategy.....	13
Table 3: Clostridium difficile interventions.....	18
Table 4: Klebsiella pneumoniae interventions.....	19
Table 5: Summary of outcomes for Clostridium difficile interventions.....	21
Table 6: Summary of outcomes for Klebsiella pneumoniae interventions.....	24

Table of figures

Figure 1: PRISMA flow diagram.....	15
Figure 2: Proportion of staff involvement across studies	17

Introduction

Over the past centuries, infectious diseases have claimed millions of lives presenting a real threat to human existence ¹. The discovery of antimicrobial agents during the 19th and 20th century was a bold step in reducing the morbidity and mortality associated with infections ². Observations by Alexander Fleming on the effect of *Penicillium* on bacteria cultures birthed the era of anti-infective agents ³. In 1947, Waksman, coined the term “antibiotic” in reference to a chemical agent capable of destroying or inhibiting the growth of microorganisms ⁴. Progressively, clinicians recognised antibiotics as an effective strategy for treating and eradicating pathogenic microorganisms.

As the use of antibiotics gained popularity worldwide, a new threat emerged from the over-reliance on these life-saving therapeutic agents ⁵. More than 50% of antimicrobials’ use is deemed as either inappropriate or unnecessary. Within the last two decades alone, the use of antimicrobial agents has risen by 65% with available evidence confirming this as a key driver of resistance ⁶. Coupled with the rapid human to human transmission of pathogens ⁷, infectious microorganisms have continued to undergo adaptive evolution rendering a wide range of antimicrobial agents ineffective ⁸⁻¹⁰. Consequently, infections have become even more potent as microorganisms continuously acquire resistance against previously effective antibiotics.

Today, infectious diseases remain top on the list of the leading causes of death globally based on recent statistics by the World Health Organization (WHO) ¹¹. Even more worrying are the deaths attributable to multi-drug resistant microorganisms (MDROs) that have continued to increase over the past decade. A modelling analysis reported 33,000 deaths associated with resistant bacteria in Europe in 2015, revealing a significant rise since 2007 ¹². Another study reported a mortality rate of 23,000 deaths in the United States associated with resistant bacteria ¹³.

Healthcare settings provide a perfect breeding ground for the transmission of resistant pathogens to susceptible hosts. According to the European Center for Disease Prevention and Control (ECDC), the EU records an estimated 3.2 million healthcare associated infections (HAIs) and an associated 37,000 deaths annually¹⁴. The burden of HAIs within the EU translates to an estimated 2.5 million DALYs, 16 million additional hospitalization days, and an annual economic burden of 7 billion euros^{15,16}. A significant proportion of the HAIs burden is attributable to multi-drug resistant pathogens¹⁷.

Some of the multi-drug resistant pathogens associated with HAIs include *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas spp*, *Escherichia coli*, *Clostridium (Clostridioides) difficile*, and *Enterococci spp*¹⁸⁻²¹. These are also commonly referred to as the ESKAPE pathogens. For purposes of this study, we focused our attention on the research undertaken on *Clostridium difficile* (*C. diff*) and *Klebsiella pneumoniae* in healthcare settings.

Clostridium difficile accounts for the largest proportion of hospital-acquired diarrhoea with antimicrobial therapy being a key determinant for *C. diff* infections (CDIs)²². Approximately 453,000 cases of CDIs and 29,300 fatalities were reported in the United States over a period of one year²³. An European based study reported a 55% resistance rate of *C. diff* in isolates²² obtained from European populations. There is a large body of evidence confirming the transmission of *C. diff* within hospital environments^{24,25}, hence, the importance of proactive steps for mitigation.

On the other hand, a recent surveillance report on HAIs by the National Healthcare Safety Network reported a 9% prevalence of *Klebsiella pneumoniae* amongst hospitalized adult patients¹⁷. This is a marginal increase considering a prior survey that reported an 8% prevalence of *Klebsiella pneumoniae* between 2011 and 2014²⁶. A similar trend is evident in

pediatric intensive care units that recorded a 9% prevalence of *Klebsiella pneumoniae* between 2011 to 2014²⁷.

Surveillance and resistance patterns

Clostridium difficile

There exist various approaches used in the surveillance of *Clostridium difficile* infections and resistance patterns. These methods include genomic analysis^{28,29}, polymerase chain reaction (PCR) ribotyping³⁰⁻³², as well as molecular characterization of isolates³³⁻³⁶. Based on PCR-ribotyping, the resistant strains of *Clostridium difficile* examined by previous studies are mainly associated with ribotypes 012, 017, 018, 027, 053, 078, 176, and 630³⁷⁻⁴³.

Literature on the resistance patterns of *Clostridium difficile* reveals reduced susceptibility of the bacteria to fluoroquinolones^{40,44}, Macrolide-Lincosamide-Streptogramin B (MSLB) antibiotics³¹, erythromycin⁴⁵, clindamycin⁴⁶, moxifloxacin⁴⁷, rifampicin⁴⁸, rifamycin⁴⁹, metronidazole^{50,51}, cadazolid⁵², linezolid⁵³, imipenem³⁸, vancomycin^{54, 55, 56}, and fidaxomicin⁵⁴. Studies have also shown that various factors contribute to *Clostridium difficile* resistance. These factors include wrong use of antibiotics⁵⁷, intestinal microbiota⁵⁸, overuse of antibiotics such as rifampicin in TB patients⁴⁸, immunosuppression^{59,60}, gut dysbiosis⁶¹, and cancer treatment⁶¹.

Klebsiella pneumoniae.

The risk factors for *Klebsiella pneumoniae* resistance include hospitalization, recent antibiotics use, surgery, and renal failure^{62,63} in adults whereas paediatric patients with a history of low birth weight, prolonged hospitalization, and prematurity are more susceptible to the resistant strains of *Klebsiella pneumoniae*⁶⁴. The surveillance methods for *Klebsiella pneumoniae* include Whole Genome Sequencing (WGS), Metagenomic Sequencing⁶⁵⁻⁶⁸, isothermal DNA assays⁶⁹, and pulsed field gel electrophoresis⁷⁰.

There is demonstrable evidence of *Klebsiella pneumoniae* resistance against carbapenem, imipenem, meropenem, aminoglycosides, amoxicillin, amikacin, ampicillin/piperacillin, ciprofloxacin, levofloxacin, amoxicillin-clavulanic acid, trimethoprim-sulfamethoxazole, cefepime, colistin, nitrofurantoin, amikacin, aztreonam, ceftazidime, and tigecycline ⁷¹⁻⁸⁰.

Some of the resistant strains of *Klebsiella pneumoniae* include the clones ST11, ST29, ST101, ST258, which is also less susceptible to chlorhexidine cleaning, ST307, ST347, ST607-K25, ST661, ST1224, ST2558, ST3006 ^{66,81-86}. Whereas, the genes associated with resistance in *Klebsiella pneumoniae* species include *bla*_{IMP-4}, *bla*(OXA-48), OXA-33, TEM-1, and SHV-11, *bla*(KPC), *bla*(VIM), *bla*(NDM), *wcaG*, *rpmA*, *intl1*, *bla*CTX-M-15, *qnrS1*, *qnrB1*, *aac*(6')-Ib, *aac*(6')-Ib-cr, *vagCD*, *traT*, *ccdAB*, *bla*(CTX_M_1), *bla*(TEM), *bla*(OXA-1), *fyuA*, or *cnf-1*, and *bla*(SHV) ^{73,81,87-95}.

Rationale

Antimicrobial resistance (AMR) represents a public health emergency of global magnitude with the resultant mortality rate projected at 10 million fatalities by 2050 ⁹⁶. The cost of treating resistant microorganisms has also significantly risen with evidence from the United States revealing a twofold increase between 2002 and 2015 ⁹⁷. According to the World Health Organization, antimicrobial resistance is a preventable consequence of antibiotics' misuse and overuse arising from a malfunctioned primary healthcare system ⁹⁸.

There is an urgent need to reduce the burden of AMR through multi-level approaches aimed at curbing transmission of multi-drug resistant organisms (MDROs), and optimizing the use of antibiotics. Although multiple interventions for mitigating AMR exist ⁹⁹, their implementation has not effectively addressed the problem. Interventions for reducing

transmission of MDROs are broadly categorized into horizontal measures and vertical measures¹⁰⁰.

The horizontal measures include pathogen non-specific strategies such as hand hygiene and environmental cleaning employed in disrupting the transmission¹⁰⁰. The vertical measures are pathogen-specific and may include universal or targeted screening on admission for hospital care¹⁰¹. Additional strategies such as developing new antibiotics and exploring the possibility of effective vaccines could also potentially resolve the AMR issue⁷. Considering the potential implications, curbing the human-to-human transmission of pathogens and optimizing antimicrobials' use appear to be the low hanging fruits with far reaching impact.

By focussing on *Clostridium difficile* and *Klebsiella pneumoniae*, we explored the widely researched topic of AMR specifically on the effectiveness of interventions targeting the drug resistant pathogens. Our preliminary exploration of literature retrieved three scoping reviews on antimicrobial misuse and interventions to address AMR. None of these scoping reviews paid attention to either *Clostridium difficile* or *Klebsiella pneumoniae*.

The first scoping review¹⁰² was limited to dentistry settings while a second review¹⁰³ examined literature on knowledge, attitudes, and practices amongst community pharmacists. Lastly, the final scoping review retrieved by the researchers focussed on the supply related interventions for reducing prescription of antibiotics in low-to-middle-income countries⁹⁹.

This scoping review is relevant because it expands the breadth of existing reviews by mapping out recent evidence on interventions for reducing *Clostridium difficile* and *Klebsiella pneumoniae* transmissions within healthcare settings. Notably, we examined the amount of research on antimicrobial stewardship interventions aimed at optimizing antimicrobial agents against *Clostridium difficile* and *Klebsiella pneumoniae*.

Research objectives

This scoping review answers the broad question: What is the breadth of the available literature on the interventions for reducing *Clostridium difficile* and *Klebsiella pneumoniae* transmission in healthcare settings? The review addresses the following objectives:

1. To assess the breadth of studies on antibiotics stewardship *C. diff* and *Klebsiella pneumoniae* in healthcare settings.
2. To identify existing literature on the interventions for reducing healthcare associated *C. diff* and *Klebsiella pneumoniae* transmission.

Methods

Various methods exist for reviewing existing literature on research topics of interest namely systematic reviews, meta-analyses, and scoping reviews. Systematic reviews and meta-analyses are applicable in contexts where the research question is narrow and focused whereas scoping reviews are most preferable with broader research questions¹⁰⁴. Scoping reviews are applicable when broadly mapping literature for purposes of identifying main concepts, theoretical perspectives, available evidence, and gaps in literature¹⁰⁵. Considering the broad nature of the present topic namely antimicrobial stewardship interventions in healthcare settings, the scoping review approach was justified.

Arksey and O'Malley proposed a five-stage framework for undertaking scoping reviews¹⁰⁶. This approach is rigorous and enhances the transparency of the findings as sufficient detailing of the procedures employed allow for replication. The use of explicit approaches improves the reliability of the study and highlights the robustness of the employed methods¹⁰⁷. The stages for conducting a scoping review entail identification of a research question, identifying applicable studies, selecting studies for review, data charting, and collation of results, summarising, and report compilation¹⁰⁶.

Research protocol

Scoping review guidelines emphasize on the importance of providing information regarding the protocol for a scoping review undertaken for purposes of improving transparency and minimising the risk for duplication¹⁰⁸. In the event that the protocol is publicly unavailable, authors should provide contact details or corresponding details through which other researchers can make requests to access it. The research team developed and reviewed a research protocol for this scoping review which is available upon request through bernardokeah@gmail.com or brk18vjr@bangor.ac.uk.

This scoping review was undertaken and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) guidelines¹⁰⁸. This approach integrates the five-stages proposed by Arksey and O'Malley with regard to the conduct of scoping reviews¹⁰⁶. Subsequently, members of the research team reviewed this protocol prior to its online registration.

Eligibility criteria

The review included peer-reviewed studies that either focus on reducing healthcare associated transmission of *C. diff* and *Klebsiella pneumoniae* or optimizing the use of antibiotics in relation to the aforementioned pathogens. Studies involving human participants published in English over the last ten years constituted part of this scoping review. Lastly, the research team considered quantitative and/ or experimental studies on the present research topic. The researchers excluded outbreak investigations that did not report any outcomes on the transmission of *C. diff* or *K. pneumoniae*. The research team also excluded studies that explored new diagnostic devices or therapeutic interventions with no outcomes on the hospital transmission of *C. diff* or *Klebsiella pneumoniae*.

Table 1: Eligibility criteria

	Proposed criteria	Refined criteria
Population/ Setting	Healthcare facilities	Healthcare facilities
Intervention/ Exposure	AMS interventions for <i>C. diff</i> or <i>Klebsiella pneumoniae</i>	Optimizing use of antimicrobials or curbing transmission of <i>C. diff</i> and/ or <i>Klebsiella pneumoniae</i>
Comparison	No intervention	No intervention
Outcome	Control of <i>C. diff</i> and/ or <i>Klebsiella pneumoniae</i>	Appropriate use of antimicrobials Reduced risk/ transmission of <i>C. diff</i> and/ or <i>Klebsiella pneumoniae</i>
Study designs	All study designs	Observational studies, quasi-experimental studies, randomised controlled trials (RCTs)

Information sources

It is recommended that the search for existing literature should be undertaken comprehensively across various platforms in order to realise the purpose of a scoping review^{106,108,109}. For purposes of this review, the search for literature spanned across electronic databases accessible through the Bangor University library search engine, bibliographies, key journals, and websites for relevant organisations.

The specific databases searched included MEDLINE via EBSCOhost, PubMed Open Access via NCBI, Web of Science Core Collection, and CINAHL Plus via EBSCOhost. The institutional databases explored for literature search included the World Health Organisation, the British Society for Antimicrobial Chemotherapy, as well as the National Institute for Health Research.

Literature search

The search for sources was undertaken with the assistance of the Bangor University librarian. Appendix 1 below provides search strategy applied across the various databases in undertaking this scoping review. The MEDLINE search strategy is herein provided in table 2 below.

Table 2: MEDLINE search strategy

Search ID	Search Terms
S1	(MM "Clostridium difficile")
S2	(MM "Klebsiella pneumoniae")
S3	S1 OR S2
S4	(MM "Drug Resistance, Microbial+")
S5	(MM "Antimicrobial Stewardship")
S6	S4 OR S5
S7	S3 AND S6
S8	(MM "Cross Infection+")
S9	S7 AND S8
S10	S7 AND S8

Study selection

Two reviewers independently applied the inclusion and exclusion criteria on all the searched titles to select the relevant articles for this scoping review. The research team then retrieved full articles for studies that provide a best fit to the central research question. The researchers then read the full text of the retrieved studies to make a final determination of including them in the review. Disagreements between the researchers were ironed out through consensus or discussions with a third reviewer.

Data charting

The data extraction form should be as comprehensive as possible for the charting of relevant data from the identified evidence sources^{106,109}. Existing guidelines also recommend for detailing the process of developing, calibrating the charting form, the charting process, as

well as the resolution of disagreements¹⁰⁸. It is also important to update the charting form iteratively with descriptions of any revisions for improved transparency.

The research team developed a form for abstracting data in order to capture all the relevant variables from the identified sources. The standardized form allowed for extraction of the main study characteristics as well as the specific metrics relevant to the central research question of this scoping review. The form was subjected to preliminary calibration to ensure its accuracy, consistency, and reliability.

The data items extracted from each study included the reference, the study type, the study objectives, population or setting, country, the intervention, intervention duration, healthcare workers involved, outcome measures or findings, and the conclusions of the study. Two reviewers independently conducted the data abstraction, and discussed findings while updating the charting form. A third reviewer was available to adjudicate any disagreements not resolved between the two reviewers through consensus.

Results collation, summary, and report compilation

The guidelines for scoping reviews recommend that reviewers provide a comprehensive overview of the retrieved evidence¹⁰⁶. This involves organising the evidence based on the identified themes and giving a narrative account as opposed to synthesising the results. Scoping reviews are useful in mapping relevant concepts that underpin a phenomenon of interest while aggregating the existing evidence on the topic^{108,109}. The subsequent sections provide a narrative account of the existing literature on AMS interventions for *C. diff* and *Klebsiella pneumoniae* as well as any apparent gaps in line with the central review question.

Results

Selection of sources of evidence




Figure 1: PRISMA flow diagram

The search for literature across the identified databases (MEDLINE, CINAHL, PubMed, and Web of Science) retrieved 808 records whereas an additional six titles were identified through bibliographic searches. Following de-duplication, 617 titles were screened where after 493 records did not meet the inclusion criteria. The abstracts of the remaining 120 records were further screened leading to the exclusion of 44 articles. Full text reading was done for 76 articles leading to the exclusion of 42 articles and inclusion of 34 articles.

Characteristics of selected studies

16 studies focussed their investigation on *Clostridium difficile* whereas 18 articles focussed on *Klebsiella pneumoniae*. The studies varied in their designs with majority being quasi-experiments (32 articles). The other study designs included cohort studies (2 articles) and secondary analysis of a randomized controlled trial (1 article). 27 of the studies were undertaken prospectively whereas 7 studies followed a retrospective approach.

32.4% of the studies (11 studies) were conducted in the United States whereas two studies each are based in Canada and Greece. Four of the retrieved studies are from Italy while Israel and China had three studies each. Lastly, the selected articles included one study each from Japan, United Kingdom, South Africa, Denmark, Brazil, France, South Korea, Hungary, and the Netherlands.

Most of the studies (30 articles) are single site studies whereas four studies are multi-site experiments. There was diversity in the study populations with three studies involving neonates in the neonatal intensive care unit whereas 31 studies involved adult subjects admitted for care within the hospital settings.

Synthesis of results

Interventions

The studies explored a wide range of interventions targeting the use of antimicrobial agents or reducing the transmission of *Clostridium difficile* and *Klebsiella pneumoniae* within the hospital environments. The duration of interventions varied across the studies from three weeks up to six years. The interventions involved various cadres of professionals namely infectious disease (ID) experts, consultants, nurses, doctors, physicians, pharmacists, epidemiologists, laboratory personnel, microbiologists, support staff (cleaners, caregivers, housekeepers, paramedics, porters), managers, infection control staff, unspecified clinicians/medical personnel, quality improvement (QI) staff, patients, public health (PH) staff, and patient visitors. Two studies did not specify the cadres of healthcare personnel involved. The bar graph below summarizes the proportions of studies that involved various health professionals.




Figure 2: Proportion of staff involvement across studies

Most of the interventions were multi-faceted involving the implementation of at least two strategies to achieve the intended outcomes. The strategies employed in interventions targeting *Clostridium difficile* included surveillance through active screening, alert systems,

isolation, dedicated staff, environmental disinfection, audits, contact precautions, specialist consultations, checklists, antimicrobial policies, care bundles, staff education, specialised biocidal linen, and faecal microbiota transplant (FMT). Table 3 below outlines the combination of these interventions across the identified studies.

Table 3: Clostridium difficile interventions

Interventions	References															
	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125
Surveillance/ Screening							✓					✓				
Alerts and notifications							✓					✓			✓	
Isolation and contact precautions						✓	✓					✓		✓	✓	✓
Environmental disinfection										✓				✓		✓
Audits and feedback	✓		✓	✓		✓					✓	✓	✓			
Checklists			✓													
Antimicrobial policies and/ protocols		✓			✓						✓				✓	
Care bundles																✓
Staff education		✓	✓		✓						✓			✓		
Biocidal (Cu ₂ O) linen								✓	✓							
Intervention duration (months)	24	18	18	12	16	18		8	27	27	16	12	13	24		22

The commonest strategy explored by most (7) of the identified studies was the use of audits and feedback. Five studies integrated a staff education component while another five studies assessed the effectiveness of source isolation with contact precautions including dedicated staff. Restrictive antimicrobial policies and treatment protocols constituted part of four experiments.

Three studies examined the use of alerts and notifications while active surveillance through screening, environmental disinfection, and the use of biocidal linen impregnate with copper oxide were examined by two studies each. Some interventions namely environmental disinfection, audits and feedback, and biocidal linen were examined as standalone interventions.

Interventions targeting the containment or reduced transmission of *Klebsiella pneumoniae* included surveillance through active screening, alert systems, isolation with

contact precautions and dedicated staff, environmental decontamination, antimicrobial audits, specialist consultations, antimicrobial policies, care bundles, and staff or patient education.

Table 4: *Klebsiella pneumoniae* interventions

Interventions	References																	
	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143
Surveillance/ Screening	✓	✓		✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		✓	✓
Alerts and notifications	✓		✓	✓		✓		✓	✓									
Isolation with contact precautions	✓		✓			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
Environmental disinfection			✓				✓		✓	✓		✓	✓	✓				
Audits and feedback				✓		✓				✓				✓				
Consultations							✓											
Antimicrobial policies and protocols	✓			✓	✓												✓	
Care bundles												✓						
Staff education and/ patient education			✓	✓						✓				✓		✓		
Intervention duration (months)	36	14	48	36	24	14	2	36	6	17	4	24	8	<1	2	72	3	6

The commonest strategy that constituted part of 15 interventions targeting *Klebsiella pneumoniae* was surveillance through active screening and cultures. Source isolation with contact precautions formed part of 14 interventions followed by environmental disinfection (7 studies). Alerts and notification systems were integrated in six interventions whereas education strategies formed part of five interventions. Academic detailing (audits and feedback) and restrictive antimicrobial policies were each examined by four studies. Standalone interventions reported by identified studies included the use of specialist consultations and care bundles targeting *Klebsiella pneumoniae*.

Outcomes

The key outcome measures reported across the studies included consumption of targeted antimicrobials, incidence of *Clostridium difficile* or *Klebsiella pneumoniae*, containment of an outbreak of the targeted organisms, adherence to IPC measures, and hospital stay, and mortality.

Clostridium difficile

Table 5 below summarizes some key outcome measures based on the findings as reported by the included studies.

Antimicrobial use

Seven studies reported variations in the consumption of antimicrobial agents following the stewardship interventions. The changes in antimicrobial use are reported in daily defined doses per 1000 patient days (DDD/1000PDs). Reduced use of antimicrobials ranged between 6.58 DDDs/1000 PDs and 310 DDDs/1000 PDs.

The largest absolute reduction in antimicrobial use of 310 DDs/1000PDs was reported from an intervention that involved audits and feedback systems ¹¹⁰. However, this reduction was the least in proportionate terms (11%) compared to the largest proportional reduction in antimicrobials use of 79% after an intervention involving restrictive antimicrobial policies and staff education ¹¹⁴.

In terms of antimicrobial costs, the largest reduction (54%) was reported from an intervention involving staff education, audits, consultations, and checklists ¹¹². One study reported a 52% improvement in antimicrobial streamlining after undertaking audits and feedbacks for targeted antimicrobial agents ¹²².

Table 5: Summary of outcomes for Clostridium difficile interventions

Key outcomes	References															
	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125
Antimicrobials use (DDD/1000PDs)	↓310	↓200		↓6.58	↓124	↓141					↓34	↓10.7				
Antimicrobials use (% reduction)	11%	47%	46%		79%	22%					12%	37%				
Antibiotics cost (↓%)			↓54			↓24							↓51			
Antimicrobials streamlining (%/week)													↑52			
Resistance rates																
CD risk/100,000 or/10000PDs (post-intervention)	⇔	12		14	55	60			2.8	170	2.8	11	16	⇔		85
CD absolute risk (%)	⇔	↓67	↓46	↓83	↓77	↓31		↓51	↑87	↓5	↓71	↓36	↓71	⇔		↓37
Risk for HCAs (AR)		↓25								⇔		↓				↓
% reduction in time for start of treatment															64	
Time savings (hrs/1000 admissions)							↓43									
Hospital stay																
Adherence to contact precautions (%)			↑80						↓6							↑95
Mortality		⇔														

DDD: Daily defined doses; PD: Patient days; CD: Clostridium difficile; HCAs: Healthcare associated infections; AR: Absolute risk, ↓: Reduced ↑: Increases; ⇔:

Remained the same; ●: Outbreak was contained.

Risk for CDIs, other HCAIs, and associated mortality

Fourteen studies reported the impact of the interventions on the risk for CDIs or other healthcare associated infections. One study involving audits and feedbacks¹¹⁰ did not observe any changes in the hospital associated risk for CDIs same as a second study that entailed staff education, environmental disinfection, and isolation precautions¹²³. Another study that assessed the efficacy of audits and feedback interventions reported the highest overall reduction of 83% in absolute risk for CDIs¹¹³.

Regarding the effect of CDI interventions on other HCAIs, one study reported a 25% absolute risk reduction for other HCAIs¹¹¹, a second study reported no effect¹¹⁹, while a third study simply indicated there was a reduction in the risk of other HCAIs¹²¹. Only one study involving staff education and restrictive antimicrobial policies reported on CDI associated mortality whereby no differences were observed between the experimental and control groups¹¹¹. Two studies involving the use of biocidal linen impregnated with copper oxide reported contradictory findings whereby one study reported a 51% reduction in the risk for CDIs¹¹⁷ whereas the second study reported an 87% increase in the risk of CDIs¹¹⁸.

Adherence to contact precautions

One study involving staff education, checklists, and audits as well as feedbacks reported an 80% improvement in adherence to contact precautions for staff managing patients with CDIs¹¹². The highest improvement (95%) in adherence was reported by a 22-months intervention involving the use of an infection prevention bundle and an environmental cleaning protocol¹²⁵. On the other hand, an intervention involving the use of biocidal linen impregnated with copper oxide reported a 6% reduction in adherence to contact precautions¹¹⁸. The non-adherence in the latter study was associated with the increased risk of *Clostridium difficile*.

Time savings

Only two studies reported outcomes related to time savings whereby one intervention involving antimicrobials restriction, alerts and notifications, and isolation precautions recorded a 64% reduction in time prior to the initiation of appropriate antibiotics treatment¹²⁴. A second study involving active surveillance, alerts, and contact precautions reported a 43% reduction in care hours per 1000 admissions¹¹⁶.

Klebsiella pneumoniae

Table 6 below summarizes the evidence on outcome measures as reported by interventions targeting the containment of *Klebsiella pneumoniae* within healthcare settings.

Antimicrobials use

Only three studies reported on antimicrobial use with regards to *Klebsiella pneumoniae* interventions. One study involving screening, alerts, isolation precautions, and antimicrobial policies simply indicated there was a reduction in the use of targeted antimicrobial agents¹²⁶. A study involving screening, alerts, staff education, and antimicrobial protocols recorded a 75% reduction in the use of targeted antimicrobials¹²⁹. The last study involving restrictive antimicrobial policies reported a 21% (12.9 DDDs/1000 PDs) reduction in the use of targeted antimicrobial agents¹³⁰.

Table 6: Summary of outcomes for Klebsiella pneumoniae interventions

Key outcomes	References																	
	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143
Antimicrobial use (DDD/1000PDs)	↓				13													
Antimicrobials use (% reduction)				↓75	↓21													
Antibiotics cost (↓%)																		
Antimicrobials streamlining (%/week)																		
Resistance rates		↓			↔				●							↓		
KP risk/100,000 or/10000PDs	18		0.5	23%		↓	56		↓	↓	●	28				0.9	↓	
KP absolute risk (%)	↓97		↓92	↓17		12	12	●	●	10	●		●	●	●	46	↓	●
Risk for HCAs (AR)			↓55							↑59		↓84						
% reduction in time for start of Rx																		
Time savings (hrs/1000 admissions)																		
Hospital stay (%PDs)																		↓15
Adherence to contact precautions (%)								↑	↑	↑			↑			↑35	↑29	
Mortality																		

DDD: Daily defined doses; PDs: Patient days; HCAs: Healthcare associated infections; AR: Absolute risk, ↓: Reduced ↑: Increases; ↔: Remained the same; ●: Outbreak was contained

Risk for *Klebsiella pneumoniae*, other HCAs, and associated mortality.

Seven studies reported on containment of *Klebsiella pneumoniae* outbreaks with no outcomes on the residual risk for the bacteria^{133,134,136,138–140,143}. Two interventions involving active surveillance through screening¹²⁷ and staff education combined with isolation precautions¹⁴¹ reported a reduction in the resistant rates of *Klebsiella pneumoniae*. An intervention involving antimicrobial restrictions and protocols recorded no changes in the resistance rates of *Klebsiella*¹³⁰.

Regarding the absolute risk of *Klebsiella pneumoniae*, the largest risk reduction (97%) was seen in an intervention that combined screening, alerts, isolation/ contact precautions, and antimicrobial protocols¹²⁶. The lowest reduction in absolute risk was recorded from a multi-faceted intervention that entailed screening, isolation/ contact precautions, audits and feedback, and staff education¹³⁵.

An intervention involving staff education, isolation, environmental cleaning, alerts reported a 55% reduction in other HCAs¹²⁸ while a second intervention comprising of screening, isolation, environmental disinfection, and care bundles reported an 84% reduction in other HCAs¹³⁷. On the other hand, one study reported a 59% rise in the risk of other HCAs following an intervention that involved screening, isolation, environmental decontamination, audits, and education¹³⁵. There are no studies that reported on the impact of interventions on mortality associated with *Klebsiella pneumoniae* in healthcare settings.

Hospital stay and adherence to contact precautions

Only one study recorded outcomes associated with hospital stay whereby there was a 15% reduction in the hospitalization duration¹⁴² that was also associated with 29% increase in adherence with contact precautions. An intervention involving staff education also reported a 35% improvement in adherence to contact precautions¹⁴¹. Lastly, four additional studies

also reported an improvement in adherence to contact precautions although this was not reported in numerical values^{132–134,138}.

Discussion

Summary of evidence

In this scoping review, we identified 34 articles on the antimicrobial stewardship interventions for *C. diff* and *KP* in healthcare settings published between 2010 and 2019. Antimicrobial stewardship interventions identified by this review included restrictive antimicrobial policies and treatment protocols, specialists' consultations, notifications and alert systems, audits combined with feedback (also referred to as academic detailing).

On the other hand, interventions aimed at curbing the healthcare associated transmission of *C. diff* and *Klebsiella pneumoniae* included surveillance through active screening and cultures, isolation and contact precautions, environmental disinfection, use of care bundles, and education of staff and or patients. There was an additional intervention specific to *Clostridium difficile* namely the use of biocidal linen impregnated with copper oxide.

We propose the abbreviation ESCAPE-BIN (**E**ducation, **S**urveillance/**S**creening, **C**onsultations, **A**udits, **P**olicies/**P**rotocols, **E**nvironmental disinfection, **B**undles, **I**solation, and **N**otifications or alerts) to denote the common interventions for disrupting the transmission cycle of *Clostridium difficile* and *Klebsiella pneumoniae* in healthcare settings

Our review found that most interventions targeting *C. diff* tended to integrate a component of restrictive antimicrobial policies or treatment protocols whereas interventions targeting *Klebsiella pneumoniae* mainly incorporated screening, contact precautions, or environmental disinfection as core strategies.

This review established a paucity of evidence on the application of care bundles and specialist consultations in mitigating the healthcare associated transmission of *Clostridium difficile* and *Klebsiella pneumoniae*. In addition, there was very limited evidence on the effect of interventions on adherence to antimicrobial treatment protocols as well as isolation and contact precautions targeting the *C. diff* and *Klebsiella pneumoniae*.

Limitations

There are some limitations to this scoping review. In the first place, quality assessment was not undertaken for the included studies because the main purpose of this review was basically mapping out potential sources of evidence on the topic of interest. Secondly, the study population and settings of included articles were very diverse and no adjustments were undertaken to account for these differences. Lastly, the researchers did not take into account the duration of the specific interventions undertaken to mitigate *Clostridium difficile* and *Klebsiella pneumoniae* in healthcare settings.

Conclusions

Antimicrobial resistance represents a global threat requiring urgent measures to protect lives. Reducing the burden of AMR entails a host of multi-level approaches aimed at curbing transmission of the resistant pathogens, and optimizing the use of antibiotics. In this review, we identified the antimicrobial stewardship as well as infection control interventions targeting *Clostridium difficile* and *Klebsiella pneumoniae*. These interventions include **E**ducation, **S**urveillance/Screening, **C**onsultations, **A**udits, **P**olicies/**P**rotocols, **E**nvironmental disinfection, **B**undles, **I**solation, and **N**otifications or alerts (ESCAPE-BIN). However, there is a further need for investigations on the application of care bundles, specialist consultations, and adherence to contact precautions.

References

1. Mohr, K. I. History of antibiotics research. *Curr. Top. Microbiol. Immunol.* **398**, 237–272 (2016).
2. Clardy, J., Fischbach, M. A. & Currie, C. R. The natural history of antibiotics. *Current Biology* vol. 19 (2009).
3. Fleming, A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *Br. J. Exp. Pathol.* **10**, 226–236 (1929).
4. Waksman, S. What is an Antibiotic or an Antibiotic Substance? *Mycologia* **39**, 565–569 (1947).
5. Zaffiri, L., Gardner, J. & Toledo-Pereyra, L. H. History of antibiotics. from salvarsan to cephalosporins. *Journal of Investigative Surgery* vol. 25 67–77 (2012).
6. Klein, E. Y. *et al.* Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E3463–E3470 (2018).
7. Huttner, A. *et al.* Antimicrobial resistance: A global view from the 2013 World Healthcare-Associated Infections Forum. *Antimicrobial Resistance and Infection Control* vol. 2 (2013).
8. Légaré, F. *et al.* Training family physicians in shared decision-making to reduce the overuse of antibiotics in acute respiratory infections: A cluster randomized trial. *CMAJ* **184**, (2012).
9. Alumran, A., Hou, X. Y. & Hurst, C. Assessing the overuse of antibiotics in children in Saudi Arabia: Validation of the parental perception on antibiotics scale (PAPA

- scale). *Health Qual. Life Outcomes* **11**, (2013).
10. Martin, M. J., Thottathil, S. E. & Newman, T. B. Antibiotics overuse in animal agriculture: A call to action for health care providers. *American Journal of Public Health* vol. 105 2409–2410 (2015).
 11. World Health Organization. WHO - The top 10 causes of death. 1–7 <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> (2018).
 12. Gasser, M., Zingg, W., Cassini, A. & Kronenberg, A. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in Switzerland. *The Lancet Infectious Diseases* vol. 19 17–18 (2019).
 13. Gross, M. Antibiotics in crisis. *Curr. Biol.* **23**, (2013).
 14. Zarb, P. *et al.* European Centre for Disease Prevention and Control. *Surveillance report - Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals.* *Eurosurveillance* vol. 17 (2012).
 15. Antonioli, P. *et al.* A 2-year point-prevalence surveillance of healthcare-associated infections and antimicrobial use in Ferrara University Hospital, Italy. *BMC Infect. Dis.* **20**, (2020).
 16. Cassini, A. *et al.* Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. *PLoS Med.* **13**, (2016).
 17. Weiner-Lastinger, L. M. *et al.* Antimicrobial-resistant pathogens associated with pediatric healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. *Infect. Control Hosp. Epidemiol.* **41**, 19–30 (2020).

18. Baptista, A. B., Ramos, J. M. M., das Neves, R. R., de Souza, D. F. & Pimenta, R. S. Diversity of environmental and patients bacteria in the Hospital Geral de Palmas-TO. *J. BIOENERGY FOOD Sci.* **2**, 160–164 (2015).
19. Singh, N. P., Rani, M., Gupta, K., Sagar, T. & Kaur, I. R. Changing trends in antimicrobial susceptibility pattern of bacterial isolates in a burn unit. *BURNS* **43**, 1083–1087 (2017).
20. Gundogdu, A., Kilic, H., Ulu-Kilic, A., Aydin, G. & Alp, E. Epidemiological Features of Nosocomial Bloodstream Infections in Pediatric Patients. *KLIMIK J.* **29**, 29–35 (2016).
21. Liu, S., Wang, M., Zheng, L. & Guan, W. Antimicrobial Resistance Profiles of Nosocomial Pathogens in Regional China: A Brief Report from Two Tertiary Hospitals in China. *Med. Sci. Monit.* **24**, 8602–8607 (2018).
22. Spigaglia, P. *et al.* Multidrug resistance in European Clostridium difficile clinical isolates. *J. Antimicrob. Chemother.* **66**, 2227–2234 (2011).
23. Bouwknegt, M. *et al.* Burden of Clostridium difficile infection in the United States. *N. Engl. J. Med.* **372**, 2368 (2015).
24. Hooker, E. A. *et al.* Decreasing Clostridium difficile health care-associated infections through use of a launderable mattress cover. *Am. J. Infect. Control* **43**, 1326–1330 (2015).
25. Schulz-Stubner, S., Leonards, P. & Zimmer, P. Room Occupancy-Associated Transmission of MDRO, Clostridium difficile, or Norovirus: Results From a Room Surveillance Project. *Infection control and hospital epidemiology* vol. 38 1130–1131 (2017).

26. Weiner, L. M. *et al.* Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. *Infect. Control Hosp. Epidemiol.* **37**, 1288–1301 (2016).
27. Lake, J. G. *et al.* Pathogen Distribution and Antimicrobial Resistance Among Pediatric Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2011–2014. *Infect. Control Hosp. Epidemiol.* **39**, 1–11 (2018).
28. Lebel, S., Bouttier, S. & Lambert, T. The *cme* gene of *Clostridium difficile* confers multidrug resistance in *Enterococcus faecalis*. *FEMS Microbiol. Lett.* **238**, 93–100 (2004).
29. Adams, H. M., Li, X., Mascio, C., Chesnel, L. & Palmer, K. L. Mutations associated with reduced surotomycin susceptibility in *Clostridium difficile* and *Enterococcus* species. *Antimicrob. Agents Chemother.* **59**, 4139–4147 (2015).
30. Krutova, M., Matejkova, J., Drevinek, P., Kuijper, E. J. & Nyc, O. Increasing incidence of *Clostridium difficile* ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. *Eur. J. Clin. Microbiol. Infect. Dis.* **36**, 2251–2258 (2017).
31. Solomon, K. *et al.* PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical *Clostridium difficile* isolates. *J. Antimicrob. Chemother.* **66**, 1976–1982 (2011).
32. Piepenbrock, E., Stelzer, Y., Berger, F. & Jazmati, N. Changes in *Clostridium* (*Clostridioides*) *difficile* PCR-Ribotype Distribution and Antimicrobial Resistance in a German Tertiary Care Hospital Over the Last 10 Years. *Curr. Microbiol.* **76**, 520–526 (2019).

33. Shoaeei, P. *et al.* Molecular epidemiology of Clostridium difficile infection in Iranian hospitals 11 Medical and Health Sciences 1117 Public Health and Health Services. *Antimicrob. Resist. Infect. Control* **8**, (2019).
34. Berger, F. K. *et al.* Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon. *Int. J. Med. Microbiol.* **308**, 358–363 (2018).
35. Walkty, A. *et al.* Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates. *Diagn. Microbiol. Infect. Dis.* **66**, 419–424 (2010).
36. Tian, T. *et al.* Molecular Characterization of Clostridium difficile Isolates from Human Subjects and the Environment. *PLoS One* **11**, e0151964 (2016).
37. Dawson, L. F. *et al.* The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains. *BMC Microbiol.* **11**, 86 (2011).
38. Isidro, J. *et al.* Imipenem Resistance in Clostridium difficile Ribotype 017, Portugal. *Emerg. Infect. Dis.* **24**, 741–745 (2018).
39. Barbanti, F. & Spigaglia, P. Characterization of Clostridium difficile PCR-ribotype 018: A problematic emerging type. *Anaerobe* **42**, 123–129 (2016).
40. Carman, R. J. *et al.* Multidrug resistant Clostridium difficile ribotype 027 in southwestern Virginia, 2007 to 2013. *Anaerobe* **52**, 16–21 (2018).
41. Krutova, M., Matejkova, J., Tkadlec, J. & Nyc, O. Antibiotic profiling of Clostridium difficile ribotype 176--A multidrug resistant relative to C. difficile ribotype 027. *Anaerobe* **36**, 88–90 (2015).
42. Asojo, O. A. *et al.* Structural and biochemical analyses of alanine racemase from the

- multidrug-resistant *Clostridium difficile* strain 630. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **70**, 1922–1933 (2014).
43. Tenover, F. C., Tickler, I. A. & Persing, D. H. Antimicrobial-resistant strains of *Clostridium difficile* from North America. *Antimicrob. Agents Chemother.* **56**, 2929–2932 (2012).
 44. Baghani, A. *et al.* Highly antibiotic-resistant *Clostridium difficile* isolates from Iranian patients. *J. Appl. Microbiol.* **125**, 1518–1525 (2018).
 45. Ilchmann, C. *et al.* Comparison of resistance against erythromycin and moxifloxacin, presence of binary toxin gene and PCR ribotypes in *Clostridium difficile* isolates from 1990 and 2008. *Eur. J. Clin. Microbiol. Infect. Dis.* **29**, 1571–1573 (2010).
 46. Nyc, O. *et al.* Two Clusters of Fluoroquinolone and Clindamycin-Resistant *Clostridium difficile* PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis. *Microb. Drug Resist.* **23**, 609–615 (2017).
 47. Mena, A. *et al.* In vivo selection of moxifloxacin-resistant *Clostridium difficile*. *Antimicrob. Agents Chemother.* **56**, 2788–2789 (2012).
 48. Obuch-Woszczatyński, P. *et al.* Emergence of *Clostridium difficile* infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland. *Eur. J. Clin. Microbiol. Infect. Dis.* **32**, 1027–1030 (2013).
 49. Dang, U. T. *et al.* Rifamycin Resistance in *Clostridium difficile* Is Generally Associated with a Low Fitness Burden. *Antimicrob. Agents Chemother.* **60**, 5604–5607 (2016).
 50. Lynch, T. *et al.* Characterization of a Stable, Metronidazole-Resistant *Clostridium*

- difficile Clinical Isolate. *PLoS One* **8**, e53757 (2013).
51. Pituch, H. *et al.* [Assessment of susceptibility to metronidazole and vancomycin of *Clostridium difficile* strains isolated between 1998-2002]. *Med. Dosw. Mikrobiol.* **55**, 253–258 (2003).
 52. Caspers, P. *et al.* Different Resistance Mechanisms for Cadazolid and Linezolid in *Clostridium difficile* Found by Whole-Genome Sequencing Analysis. *Antimicrob. Agents Chemother.* **61**, (2017).
 53. Candela, T., Marvaud, J.-C., Nguyen, T. K. & Lambert, T. A cfr-like gene cfr(C) conferring linezolid resistance is common in *Clostridium difficile*. *Int. J. Antimicrob. Agents* **50**, 496–500 (2017).
 54. Leeds, J. A., Sachdeva, M., Mullin, S., Barnes, S. W. & Ruzin, A. In vitro selection, via serial passage, of *Clostridium difficile* mutants with reduced susceptibility to fidaxomicin or vancomycin. *J. Antimicrob. Chemother.* **69**, 41–44 (2014).
 55. Mascio, C. T. M., Chesnel, L., Thorne, G. & Silverman, J. A. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in *Clostridium difficile*, *Enterococcus faecalis*, and *Enterococcus faecium*. *Antimicrob. Agents Chemother.* **58**, 3976–3982 (2014).
 56. Cermak, P. *et al.* Strong antimicrobial activity of xanthohumol and other derivatives from hops (*Humulus lupulus* L.) on gut anaerobic bacteria. *APMIS* **125**, 1033–1038 (2017).
 57. Mendez, M. N. *et al.* Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and *Clostridium difficile* infections. *Pharmacotherapy* **26**, 61–67 (2006).

58. Britton, R. A. & Young, V. B. Role of the intestinal microbiota in resistance to colonization by *Clostridium difficile*. *Gastroenterology* **146**, 1547–1553 (2014).
59. Adams, D. J., Eberly, M. D., Goudie, A. & Nylund, C. M. Rising Vancomycin-Resistant Enterococcus Infections in Hospitalized Children in the United States. *Hosp. Pediatr.* **6**, 404–411 (2016).
60. Seril, D. N., Ashburn, J. H., Lian, L. & Shen, B. Risk factors and management of refractory or recurrent *clostridium difficile* infection in ileal pouch patients. *Inflamm. Bowel Dis.* **20**, 2226–2233 (2014).
61. Dicks, L. M. T., Mikkelsen, L. S., Brandsborg, E. & Marcotte, H. *Clostridium difficile*, the Difficult ‘Kloster’ Fuelled by Antibiotics. *Curr. Microbiol.* **76**, 774–782 (2019).
62. Jimenez, A., Alvarado, A., Gomez, F., Carrero, G. & Fajardo, C. Risk factors associated with the isolation of extended spectrum betalactamases producing *Escherichia coli* or *Klebsiella pneumoniae* in a tertiary care hospital in Colombia. *BIOMEDICA* **34**, 16–22 (2014).
63. Durdu, B. *et al.* Risk Factors Affecting Patterns of Antibiotic Resistance and Treatment Efficacy in Extreme Drug Resistance in Intensive Care Unit-Acquired *Klebsiella Pneumoniae* Infections: A 5-Year Analysis. *Med. Sci. Monit.* **25**, 174–183 (2019).
64. Rettedal, S., Hoyland Lohr, I., Natas, O., Sundsfjord, A. & Oymar, K. Risk factors for acquisition of CTX-M-15 extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* during an outbreak in a neonatal intensive care unit in Norway. *Scand. J. Infect. Dis.* **45**, 54–58 (2013).
65. Malek, A. *et al.* Next-Generation-Sequencing-Based Hospital Outbreak Investigation

- Yields Insight into *Klebsiella aerogenes* Population Structure and Determinants of Carbapenem Resistance and Pathogenicity. *Antimicrob. Agents Chemother.* **63**, (2019).
66. Chi, X. *et al.* Genomic Analysis Of A KPC-2-Producing *Klebsiella Pneumoniae* ST11 Outbreak From A Teaching Hospital In Shandong Province, China. *Infect. Drug Resist.* **12**, 2961–2969 (2019).
67. Mu, A. *et al.* Reconstruction of the Genomes of Drug-Resistant Pathogens for Outbreak Investigation through Metagenomic Sequencing. *MSphere* **4**, (2019).
68. Zautner, A. E. *et al.* Monitoring microevolution of OXA-48-producing *Klebsiella pneumoniae* ST147 in a hospital setting by SMRT sequencing. *J. Antimicrob. Chemother.* **72**, 2737–2744 (2017).
69. Renner, L. D. *et al.* Detection of ESKAPE Bacterial Pathogens at the Point of Care Using Isothermal DNA-Based Assays in a Portable Degas-Actuated Microfluidic Diagnostic Assay Platform. *Appl. Environ. Microbiol.* **83**, (2017).
70. Bernaschi, P. *et al.* Microbial tracking of multidrug-resistant *Klebsiella pneumoniae* isolates in a pediatric hospital setting. *Int. J. Immunopathol. Pharmacol.* **26**, 463–472 (2013).
71. Wu, D., Huang, X., Jia, C., Liu, J. & Wan, Q. Clinical Manifestation, Distribution, and Drug Resistance of Pathogens Among Abdominal Solid Organ Transplant Recipients With *Klebsiella pneumoniae* Infections. *Transplant. Proc.* **52**, 289–294 (2020).
72. Humayun, A. *et al.* Incidence of metallo-beta-lactamase-producing *Klebsiella pneumoniae* isolates from hospital setting in Pakistan. *Int. Microbiol.* **21**, 73–78 (2018).
73. Kryzhanovskaya, O. A. *et al.* Antibiotic Resistance and Its Molecular Mechanisms in

- Carbapenem-Nonsusceptible Klebsiellapneumoniae Isolated in Pediatric ICUs in Moscow. *Antibiot. i khimioterapiia = Antibiot. chemotherapy [sic]* **61**, 22–26 (2016).
74. Moghadas, A. J., Kalantari, F., Sarfi, M., Shahhoseini, S. & Mirkalantari, S. Evaluation of Virulence Factors and Antibiotic Resistance Patterns in Clinical Urine Isolates of Klebsiella pneumoniae in Semnan, Iran. *JUNDISHAPUR J. Microbiol.* **11**, (2018).
75. Aljanaby, A. A. J. & Alhasnawi, H. M. R. J. Phenotypic and Molecular Characterization of Multidrug Resistant Klebsiella pneumoniae Isolated from Different Clinical Sources in Al-Najaf Province-Iraq. *Pakistan J. Biol. Sci. PJBS* **20**, 217–232 (2017).
76. Metan, G., Ilbay, A., Eser, O. K., Unal, S. & Zarakolu, P. A Silent Epidemic of Colistin- and Carbapenem-Resistant Enterobacteriaceae at a Turkish University Hospital. *Infect. Control Hosp. Epidemiol.* **38**, 254–257 (2017).
77. Aracil-Garcia, B. *et al.* Rapid increase in resistance to third generation cephalosporins, imipenem and co-resistance in Klebsiella pneumoniae from isolated from 7,140 blood-cultures (2010-2014) using EARS-Net data in Spain. *Enferm. Infec. Microbiol. Clin.* **35**, 480–486 (2017).
78. Halaby, T. *et al.* Genomic Characterization of Colistin Heteroresistance in Klebsiella pneumoniae during a Nosocomial Outbreak. *Antimicrob. Agents Chemother.* **60**, 6837–6843 (2016).
79. Zheng, B. *et al.* Genome sequencing and genomic characterization of a tigecycline-resistant Klebsiella pneumoniae strain isolated from the bile samples of a cholangiocarcinoma patient. *GUT Pathog.* **6**, (2014).

80. Fabbri, G. *et al.* Outbreak of ampicillin/piperacillin-resistant *Klebsiella pneumoniae* in a neonatal intensive care unit (NICU): investigation and control measures. *Int. J. Environ. Res. Public Health* **10**, 808–815 (2013).
81. Chen, D. *et al.* Co-outbreak of multidrug resistance and a novel ST3006 *Klebsiella pneumoniae* in a neonatal intensive care unit: A retrospective study. *Medicine (Baltimore)*. **98**, e14285 (2019).
82. Liu, L. *et al.* Carbapenem-resistant Isolates of the *Klebsiella pneumoniae* Complex in Western China: The Common ST11 and the Surprising Hospital-specific Types. *Clin. Infect. Dis.* **67**, S263–S265 (2018).
83. Naparstek, L., Carmeli, Y., Chmelnitsky, I., Banin, E. & Navon-Venezia, S. Reduced susceptibility to chlorhexidine among extremely-drug-resistant strains of *Klebsiella pneumoniae*. *J. Hosp. Infect.* **81**, 15–19 (2012).
84. Piazza, A. *et al.* Identification of bla VIM-1 Gene in ST307 and ST661 *Klebsiella pneumoniae* Clones in Italy: Old Acquaintances for New Combinations. *Microb. Drug Resist.* **25**, 787–790 (2019).
85. Peltier, F. *et al.* Characterization of a multidrug-resistant *Klebsiella pneumoniae* ST607-K25 clone responsible for a nosocomial outbreak in a neonatal intensive care unit. *J. Med. Microbiol.* **68**, 67–76 (2019).
86. Mukherjee, S. *et al.* Molecular characterization of NDM-1-producing *Klebsiella pneumoniae* ST29, ST347, ST1224, and ST2558 causing sepsis in neonates in a tertiary care hospital of North-East India. *Infect. Genet. Evol.* **69**, 166–175 (2019).
87. Eghbalpoor, F. *et al.* Antibiotic resistance, virulence and genetic diversity of *Klebsiella pneumoniae* in community- and hospital-acquired urinary tract infections in Iran. *Acta*

- Microbiol. Immunol. Hung.* **66**, 349–366 (2019).
88. Ferreira, R. L. *et al.* High Prevalence of Multidrug-Resistant *Klebsiella pneumoniae* Harboring Several Virulence and beta-Lactamase Encoding Genes in a Brazilian Intensive Care Unit. *Front. Microbiol.* **9**, (2019).
89. Moghadampour, M., Rezaei, A. & Faghri, J. The emergence of blaOXA-48 and blaNDM among ESBL-producing *Klebsiella pneumoniae* in clinical isolates of a tertiary hospital in Iran. *Acta Microbiol. Immunol. Hung.* **65**, 335–344 (2018).
90. Asencio Egea, M. A. *et al.* Monoclonal spread of multi-drug resistant CTX-M-15-producing *Klebsiella pneumoniae*. Impact of measures to control the outbreak. *Rev. Esp. Quimioter.* **31**, 237–246 (2018).
91. Kotsanas, D. *et al.* ‘Down the drain’: carbapenem-resistant bacteria in intensive care unit patients and handwashing sinks. *Med. J. Aust.* **198**, 267–269 (2013).
92. Jafari, Z. *et al.* Molecular Epidemiology and Drug Resistance Pattern of Carbapenem-Resistant *Klebsiella pneumoniae* Isolates from Iran. *Microb. DRUG Resist.* **25**, 336–343 (2019).
93. Zaki, A. O. B. A. M. E. S. Molecular Study of *Klebsiella Pneumoniae* Virulence Genes from Patients with Hospital Acquired Sepsis. *Clin. Lab.* **65**, (2019).
94. Malik, T., Naim, A. & Saeed, A. Molecular Detection of TEM, SHV and CTX-M Genes Among Gram-negative *Klebsiella* Isolates. *Curr. Drug Deliv.* **15**, 417–423 (2018).
95. Mammina, C. *et al.* Sequence type 101 (ST101) as the predominant carbapenem-non-susceptible *Klebsiella pneumoniae* clone in an acute general hospital in Italy. *Int. J. Antimicrob. Agents* **39**, 543–545 (2012).

96. Lim, J. M. *et al.* Impact of national interventions to promote responsible antibiotic use: a systematic review. *J. Antimicrob. Chemother.* (2019) doi:10.1093/jac/dkz348.
97. Thorpe, K. E., Joski, P. & Johnston, K. J. Antibiotic-resistant infection treatment costs have doubled since 2002, now exceeding \$2 billion annually. *Health Aff.* **37**, 662–669 (2018).
98. WHO. *Antimicrobial resistance and primary health care. World Health Organization (WHO)* vol. brief https://www.who.int/docs/default-source/primary-health-care-conference/amr.pdf?sfvrsn=8817d5ba_2 (2018).
99. Wilkinson, A., Ebata, A. & Macgregor, H. Interventions to reduce antibiotic prescribing in LMICs: A scoping review of evidence from human and animal health systems. *Antibiotics* vol. 8 (2019).
100. Wenzel, R. P. & Edmond, M. B. Infection control: the case for horizontal rather than vertical interventional programs. *Int. J. Infect. Dis.* **14**, (2010).
101. Afshari, A., Schrenzel, J., Ieven, M. & Harbarth, S. Bench-to-bedside review: Rapid molecular diagnostics for bloodstream infection - a new frontier? *Critical Care* vol. 16 222 (2012).
102. Stein, K. *et al.* The use and misuse of antibiotics in dentistry: A scoping review. *J. Am. Dent. Assoc.* **149**, 869-884.e5 (2018).
103. Saha, S. K., Barton, C., Promite, S. & Mazza, D. Knowledge, perceptions and practices of community pharmacists towards antimicrobial stewardship: A systematic scoping review. *Antibiotics* vol. 8 263 (2019).
104. Moher, D. *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst. Rev.* **4**, 1 (2015).

105. Cacchione, P. Z. The Evolving Methodology of Scoping Reviews. *Clin. Nurs. Res.* **25**, 115–119 (2016).
106. Arksey, H. & O'Malley, L. Scoping studies: Towards a methodological framework. *Int. J. Soc. Res. Methodol. Theory Pract.* **8**, 19–32 (2005).
107. Goodwin, N. Studying the Organisation and Delivery of Health Services: Research Methods. *Heal. Soc. Care Community* **10**, 411–412 (2002).
108. Tricco, A. C. *et al.* PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Annals of Internal Medicine* vol. 169 467–473 (2018).
109. Levac, D., Colquhoun, H. & O'Brien, K. K. Scoping studies: Advancing the methodology. *Implement. Sci.* **5**, (2010).
110. So, M. *et al.* Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study. *Clin. Microbiol. Infect.* **24**, 882–888 (2018).
111. Tedeschi, S. *et al.* An Antimicrobial Stewardship Program Based on Systematic Infectious Disease Consultation in a Rehabilitation Facility. *Infect. Control Hosp. Epidemiol.* **38**, 76–82 (2017).
112. Lee, T. C., Frenette, C., Jayaraman, D., Green, L. & Pilote, L. Antibiotic Self-stewardship: Trainee-Led Structured Antibiotic Time-outs to Improve Antimicrobial Use. *Ann. Intern. Med.* **161**, S53–S58 (2014).
113. Beaulac, K., Corcione, S., Epstein, L., Davidson, L. E. & Doron, S. Antimicrobial Stewardship in a Long-Term Acute Care Hospital Using Offsite Electronic Medical Record Audit. *Infect. Control Hosp. Epidemiol.* **37**, 433–439 (2016).
114. Dancer, S. J. *et al.* Approaching zero: temporal effects of a restrictive antibiotic policy

- on hospital-acquired *Clostridium difficile*, extended-spectrum β -lactamase-producing coliforms and methicillin-resistant *Staphylococcus aureus*. *Int. J. Antimicrob. Agents* **41**, 137–142 (2013).
115. Elligsen, M. *et al.* Audit and Feedback to Reduce Broad-Spectrum Antibiotic Use among Intensive Care Unit Patients A Controlled Interrupted Time Series Analysis. *Infect. Control Hosp. Epidemiol.* **33**, 354–361 (2012).
 116. Quan, K. A., Cousins, S. M., Porter, D. D., Puppo, R. A. & Huang, S. S. Automated tracking and ordering of precautions for multidrug-resistant organisms. *Am. J. Infect. Control* **43**, 577–580 (2015).
 117. Butler, J. P. Effect of copper-impregnated composite bed linens and patient gowns on healthcare-associated infection rates in six hospitals. *J. Hosp. Infect.* **100**, e130–e134 (2018).
 118. Madden, G. R., Heon, B. E. & Sifri, C. D. Effect of copper-impregnated linens on multidrug-resistant organism acquisition and *Clostridium difficile* infection at a long-term acute-care hospital. *Infect. Control Hosp. Epidemiol.* **39**, 1384–1386 (2018).
 119. Anderson, D. J. *et al.* Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and *Clostridium difficile*: a secondary analysis of a multicentre cluster randomised controlled trial with crossover. *Lancet. Infect. Dis.* **18**, 845–853 (2018).
 120. Moffa, M. A., Walsh, T. L., Tang, A. & Bremner, D. N. Impact of an antimicrobial stewardship program on healthcare-associated *Clostridium difficile* rates at a community-based teaching hospital. *J. Infect. Prev.* **19**, 191–194 (2018).
 121. Suzuki, H. *et al.* Impact of intensive infection control team activities on the acquisition

- of methicillin-resistant *Staphylococcus aureus*, drug-resistant *Pseudomonas aeruginosa* and the incidence of *Clostridium difficile*-associated disease. *J. Infect. Chemother.* **19**, 1047–1052 (2013).
122. Yam, P., Fales, D., Jemison, J., Gillum, M. & Bernstein, M. Implementation of an antimicrobial stewardship program in a rural hospital. *Am. J. Heal. Pharm.* **69**, 1142–1148 (2012).
123. Goltsman, G. *et al.* The impact of intensive staff education on rate of *Clostridium difficile*-associated disease in hospitalized geriatric patients. *Aging Clin. Exp. Res.* (2019) doi:10.1007/s40520-019-01424-y.
124. Polen, C. B., Judd, W. R., Ratliff, P. D. & King, G. S. Impact of real-time notification of *Clostridium difficile* test results and early initiation of effective antimicrobial therapy. *Am. J. Infect. Control* **46**, 538–541 (2018).
125. Koll, B. S. *et al.* Prevention of hospital-onset *Clostridium difficile* infection in the New York metropolitan region using a collaborative intervention model. *J. Healthc. Qual.* **36**, 35–45 (2014).
126. Borer, A. *et al.* A Multifaceted Intervention Strategy for Eradication of a Hospital-Wide Outbreak Caused by Carbapenem-Resistant *Klebsiella pneumoniae* in Southern Israel. *Infect. Control Hosp. Epidemiol.* **32**, 1158–1165 (2011).
127. Liu, P. *et al.* Active screening diminishes antibiotic resistance to main pathogenic bacteria in the ICU. *Int. J. Clin. Exp. Med.* **9**, 4685–4689 (2016).
128. Ciobotaro, P., Oved, M., Nadir, E., Bardenstein, R. & Zimhony, O. An effective intervention to limit the spread of an epidemic carbapenem-resistant *Klebsiella pneumoniae* strain in an acute care setting: from theory to practice. *Am. J. Infect.*

- Control* **39**, 671–677 (2011).
129. Andersen, S. E. & Knudsen, J. D. A managed multidisciplinary programme on multi-resistant *Klebsiella pneumoniae* in a Danish university hospital. *BMJ Qual. Saf.* **22**, 907–915 (2013).
 130. Lei Munhoz Lima, A. L. *et al.* Carbapenem stewardship - positive impact on hospital ecology. *BRAZILIAN J. Infect. Dis.* **15**, 1–5 (2011).
 131. Schwaber, M. J. *et al.* Containment of a country-wide outbreak of carbapenem-resistant *Klebsiella pneumoniae* in Israeli hospitals via a nationally implemented intervention. *Clin. Infect. Dis.* **52**, 848–855 (2011).
 132. Agodi, A. *et al.* Containment of an outbreak of KPC-3-producing *Klebsiella pneumoniae* in Italy. *J. Clin. Microbiol.* **49**, 3986–3989 (2011).
 133. Meletis, G., Oustas, E., Botziori, C., Kakasi, E. & Koteli, A. Containment of carbapenem resistance rates of *Klebsiella pneumoniae* and *Acinetobacter baumannii* in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance. *New Microbiol.* **38**, 417–421 (2015).
 134. Alrabaa, S. F. *et al.* Early identification and control of carbapenemase-producing *Klebsiella pneumoniae*, originating from contaminated endoscopic equipment. *Am. J. Infect. Control* **41**, 562–564 (2013).
 135. Geladari, A. *et al.* Epidemiological surveillance of multidrug-resistant gram-negative bacteria in a solid organ transplantation department. *Transpl. Infect. Dis.* **19**, (2017).
 136. Kassis-Chikhani, N. *et al.* Extended measures for controlling an outbreak of VIM-1 producing imipenem-resistant *Klebsiella pneumoniae* in a liver transplant centre in France, 2003-2004. *Euro Surveill.* **15**, (2010).

137. Li, M. *et al.* Infection-prevention and control interventions to reduce colonisation and infection of intensive care unit-acquired carbapenem-resistant *Klebsiella pneumoniae* : a 4-year quasi-experimental before-and-after study. *Antimicrob. Resist. Infect. Control* **8**, 8 (2019).
138. Zhou, J., Li, G., Ma, X., Yang, Q. & Yi, J. Outbreak of colonization by carbapenemase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit: Investigation, control measures and assessment. *Am. J. Infect. Control* **43**, 1122–1124 (2015).
139. Cantey, J. B. *et al.* Prompt control of an outbreak caused by extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit. *J. Pediatr.* **163**, 672–673 (2013).
140. Gaibani, P. *et al.* Successful containment and infection control of a Carbapenem-resistant *Klebsiella pneumoniae* outbreak in an Italian hospital. *New Microbiol.* **37**, 87–90 (2014).
141. Kim, N.-H. *et al.* Successful containment of carbapenem-resistant Enterobacteriaceae by strict contact precautions without active surveillance. *Am. J. Infect. Control* **42**, 1270–1273 (2014).
142. Szel, B. *et al.* Successful elimination of extended-spectrum beta-lactamase (ESBL)-producing nosocomial bacteria at a neonatal intensive care unit. *World J. Pediatr.* **13**, 210–216 (2017).
143. Snitkin, E. S. *et al.* Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing. *Sci. Transl. Med.* **4**, 148ra116 (2012).

Appendix 1: Search strategy

a. MEDLINE search strategy

Search ID	Search Terms	Results
S1	(MM "Clostridium difficile")	7,452
S2	(MM "Klebsiella pneumoniae")	8,828
S3	S1 OR S2	16,277
S4	(MM "Drug Resistance, Microbial+")	68,909
S5	(MM "Antimicrobial Stewardship")	982
S6	S4 OR S5	69,747
S7	S3 AND S6	1,649
S8	(MM "Cross Infection+")	42,792
S9	S7 AND S8	192
S10	S7 AND S8	187

b. CINAHL Plus

Search ID	Search Terms	Results
S1	(MM "Clostridium Difficile")	2,307
S2	"klebsiella pneumonia*"	2,719
S3	S1 OR S2	5,023
S4	(MM "Drug Resistance, Microbial+")	15,817
S5	(MM "Antimicrobial Stewardship")	427
S6	S4 OR S5	16,176
S7	S3 AND S6	719
S8	(MM "Cross Infection+")	27,268
S9	S7 AND S8	166
S10	S7 AND S8	160
S11	S7 AND S8	127

c. Web of Science Core Collection

Search ID	Search terms	Results
# 1	TS= "clostridium difficile" OR TS= "clostridioides difficile"	12,612
# 2	TS= "klebsiella pneumonia*"	17,207
# 3	#2 OR #1	29,679
# 4	TS= "drug resistance"	50,192
# 5	TS= "antimicrobial stewardship"	3,586
# 6	#5 OR #4	53,661
# 7	#6 AND #3	1,415
# 8	TS= "cross infection" OR TS= nosocomial	17,523

# 9	#8 AND #7	193
# 10	#8 AND #7	193
# 11	#8 AND #7	193

d. PubMed

Search ("Cross Infection"[Majr]) AND (((("Klebsiella pneumoniae"[Mesh]) OR "Clostridium difficile"[Mesh])) AND (((("Drug Resistance"[Mesh] OR "Drug Resistance, Multiple, Bacterial"[Mesh] OR "Drug Resistance, Bacterial"[Mesh] OR "Drug Resistance, Microbial"[Mesh])) OR "Antimicrobial Stewardship"[Majr])) Filters: published in the last 10 years; Humans.

Appendix 2: Data Extraction

a. *Clostridium difficile*

Reference	Study type	Aims/ objectives	Population/ Setting	Intervention	Outcome/ key findings	Conclusions	Useful notes
110	Retrospective observational time-series.	To examine the effectiveness of an antimicrobial stewardship programme on utilization and cost of antimicrobials in leukemia patients in Canada	Leukemia patients. Canada Multi-site	Academic detailing (aka Audit + Feedback) Duration: 24 months Involved: ID physician, AMR pharmacist	Utilization of antimicrobials reduced from 278DDD/100 PD to 247 DDD/100 PD CDI remained stable	AMS reduces antimicrobial use but has no effect on mortality	ISS persons have neutropenia, mostly treated with broad spectrum abx hence high risk for CDI
111	Quasi-experimental	To assess the impact of an ASP on antimicrobials use, CDIs, and AMR patterns	Rehabilitation hospital 150 beds Spinal injuries patients Bologna, Italy	Bedside ID consultation Revision of antibiotics prophylaxis protocols Staff education Duration: 18 months Involved: ID consultant, physicians, and nurses.	Abx consumption reduced from 42 to 22 DDD/ 100 PDs (Carbapenems from 13 to 0.4 DDD/100PDs, Fluoroquinolones from 11.8 to 0.99 DDD/ 100 PDs) CDIs reduced from 3.6 to 1.2 cases per 10000 PDs Prevalence of KP reduced from 42% to 17% No effect on mortality or length of stay.		
112	Quasi-experimental	To optimize the use of antibiotics through trainee-led time outs	Montreal University tertiary care hospital (417 beds) Internal medicine. 2 units, 46 beds 679 inpatients Canada	Twice-weekly time-out audits using a structured electronic checklist and monthly feedback AMS monthly education: 30 minutes to all rotating staff Duration: 18 months Involved: Consultants (ID, critical care, and general medicine)	A 46% reduction of antibiotics costs from \$149 743CAD to \$69 424 78% of the cost reduction linked with reduced use of carbapenems 80% adherence to the audit CDI reduced from 24.2 to 19.6 per 10,000 PDs	An antibiotic self-stewardship bundle to implement the CDC's suggested time-outs seems to have reduced overall costs and targeted antibiotic use.	About 50% use of abx is not necessary or inappropriate

113	Quasi-experimental	To implement an AMS program in a long-term care hospital using telemedicine Provide antimicrobial oversight To improve the quality of care by standardizing antimicrobial prescribing practices	212 bed-New England Sinai Hospital in Stoughton Massachusetts Oversight undertaken by staff from Tufts Medical Center	CDIs Offsite electronic medical record audit. Duration: 12 months Involved: ID physicians and pharmacists	An overall decrease in antimicrobials use. Overall usage of anti abx reduced by 6.58DDD/1,000 PDs A reduction in the incidence of HAIs and CDIs (from 1.4 to 0.57/1000PDs)	AMS using remote EMR audit is associated with a reduction in antimicrobials use.	
114	Quasi-experimental	To reduce the number of healthcare associated CDI cases	450-bed district general hospital Hairmyres Hospital (Glasgow, UK)	A restrictive policy on the use of ceftriaxone and ciprofloxacin Educational campaign Duration: 16 months Involved: Doctors, pharmacists and managers.	Overall reduction of targeted antimicrobials (ceftriaxone: 95% and ciprofloxacin: 72.5%) (Ceftriaxone from 46.213 to 2.129 DDD/1000PDs Ciprofloxacin from 109.804 to 30.205 DDDs/1000PDs) 77% reduction in hospital acquisition of CDIs Sustained reduction of CDIs upto 0.259 cases/ 1000 pt-beds 3 years post-intervention	Restricting the two antibiotics significantly reduced healthcare associated CDIs	
115	Prospective, controlled interrupted time series	To evaluate the impact of audit and feedback on the use of broad-spectrum antimicrobials in critical care patients	Single site 150-bed tertiary hospital Intensive care unit (3). Italy	Review of all patients on day 3 and 10 after admission with suggestions for optimizing antimicrobial use given to responsible physicians. Then placing a computer-generated progress note on the patient chart, then feedback completed on same day Critical care team Targeted antimicrobials: ceftriaxone, ceftazidime, piperacillin-tazobactam, meropenem, ertapenem, levofloxacin, ciprofloxacin, and vancomycin Duration: 18 months Involved: Consultants, pharmacists, and ID physicians	Use of broad-spectrum antimicrobials reduced from 644 to 503 therapy days per 1,000 PDs Nosocomial CDIs incidence reduced from 11 to 6	Prospective audit and feedback appears to be an effective and safe means for reducing the use of broad-spectrum antimicrobials	Approximately half of antibiotics use in hospitals is inappropriate or not necessary

116	Quasi experimental	Assessing the impact of automated tracking and ordering precautions on MDROs	University of California, Irvine Medical center 410 beds Serves trauma, burns and cancer patients.	An automated system for identifying, tracking CDIs and other MDROs that involved monitoring microbiology results, triggering chart-based alerts, ordering for appropriate contact precautions on admission as well as inactivation of the precautions. The alert was in form of a visual header banner on the HER. Duration: Involved: Physician, infection prevention team, and clinicians.	Time savings estimated at 43 hours per 1000 admissions Timely initiation of contact precautions	Automated systems integrated within the EHRs have potential for protecting patients by ensuring precautions are ordered in a timely manner. The system also contributes to time savings for IPC teams.	No report on CDI outcomes
117	Quasi-experimental	To assess the effect of biocidal copper oxide impregnated linen on HCAs CDIs	Multi-site (six hospitals). Sentara Albermarle Healthcare hospitals 1019 beds NC, USA	Replacement of linen with copper oxide impregnated linen Duration: 8 months	A reduction in C. diff associated HCAs by 41.1-61.2% per 10,000 PDs during the intervention period	The use of the biocidal impregnated copper-oxide linen significantly reduced C. diff associated HCAs as well as other MDROs	Copper has some biocidal activity against some drug resistant bacteria. Its use in hospital environments potentially reduces the bioburden of HCA pathogens
118	Quasi-experimental	To examine the effect of copper impregnated linens on MDROs and CDIs	Long-term acute care hospital (LTACH). 40-beds Charlottesville, Virginia	Copper-impregnated linens including bedsheets, pillowcases, towels, and washcloths Duration: 27 months	Copper linens were associated with a much higher rate of CDIs. (1.5 to 2.8 cases per 1000PDs) There was a reduction in the compliance with hand hygiene practices (-5.6%)	There was no beneficial effect of the copper impregnated linens	No blinding of staff members
119	Secondary analysis of a multicenter cluster RCT (BETR Disinfection)	To assess the effectiveness of disinfection strategies on C. diff incidence in hospital settings BETR (Benefits of enhanced terminal room) disinfection study	Multisite: 9 hospitals in southeastern USA	Four disinfection strategies post-discharge of MDRO or C. diff patients: Standard disinfection with quaternary ammonium solution or 10% hypochlorite (bleach) for C. diff cases. Standard disinfection + UV light or bleach + UV light for C. diff cases. Bleach strategy with 10% hypochlorite Bleach + UV light	No significant differences in the hospital-wide risk of the target organisms between standard disinfection and the other three enhanced disinfection strategies. The use of UV light as part of the disinfection strategy significantly reduced the risk of C. diff (from 18.1 to 17.2/1000PDs)	Enhanced terminal room disinfection using UV light contributed to a reduction in the risk of C. diff and VRE. Enhanced terminal room disinfection overcomes the challenges of standard disinfection and potentially reduces acquisition of C.	Contaminated healthcare environments act as sources of infectious pathogens hence the importance of enhanced terminal room disinfection.

				Duration: 27 months		diff and other MDROs.	
120	Quasi-experimental. Retrospective pre- and post-intervention	To assess the impact of an ASP intervention on HA-CDI	The Western Pennsylvania Hospital (WPH). 317-bed community teaching hospital. Approximately 6800 admissions yearly.	Education. Restriction of target antimicrobials requiring prior approval. Audit + feedback. Annual guidelines for antimicrobials use. Duration: 16 months Involved: ID physician and ID pharmacist	Significant reduction in HA-CDIs from 0.84 to 0.28 cases per 1000PDs (P=0.035). A cumulative reduction in the use of clindamycin, ceftriaxone, carbapenems, fluoroquinolones, linezolid, tigecycline (from 295.1 to 261.3 DDD/1000PDs)	Implementing an ASP program significantly reduced the incidence of HA-CDI as well as abx use	Antibiotics associated with higher rates of CDI include fluoroquinolones, clindamycin, and ceftriaxone
121	Pre- and post-intervention	To assess the impact of intensive IPC activities on MRSA, drug resistant P. aeruginosa (DRP), and C. diff acquisition.	Tsukuba Medical Center Hospital (TMCH) Japan. 409 beds. Tertiary emergency medical center.	Screening + notification of new and previous MDROs. Daily review of new patients' medical records/ microbiological results. Contact precautions or standard precautions. Monitoring inappropriate use of carbapenems and promptly instructing responsible doctors. Duration: 12 months Involved: Infection control team, doctors, and ward staff	Reduction of carbapenems' use from 28.5 to 17.8 DDD/1000PDs. Improved uptake of contact precautions. A reduction in the incidence of CDI (from 0.47 to 0.11 cases/1000PDs). Incidence of MRSA and DRP also reduced significantly	Proactive intensive ICT measures have the potential for reducing the hospital transmission of MDROs.	
122	POS	To assess the impact of a technology-mediated pharmacy-directed ASP in a rural hospital	St. Mary Medical center. 141 beds. Community hospital. Washington	Weekly antimicrobial review teleconferences involving an ID pharmacist Duration: 13 months Involved: ID consultant, physicians, doctors, QI staff, pharmacists, and microbiologists.	Pharmacy-initiated AMS interventions increased from 2.1 to 6.8 interventions per week. Antimicrobial streamlining improved from 44% to 96%. There was enhanced interdisciplinary collaboration. A 51% reduction in the cost of targeted antimicrobials.		

					HA-CDIs reduced from 5.5 to 1.6 cases per 10,000PDs		
123	ROS cross-sectional study	To assess the effect of intensive staff education on CDAD amongst hospitalized geriatrics	390-bed geriatric hospital 217 geriatric patients observed. Israel	Staff education on isolation precautions, handwashing, transporting patients within the hospital, and cleaning. Duration: 24 months Involved: ID specialist, epidemiologic nurse, clinical pharmacist, doctors, nurses, paramedics, cleaners, and porters.	There were no significant differences in the incidence of CDAD pre- and post-intervention.	Intensive staff education did not reduce the nosocomial CDAD rates but remains an important strategy	Toxin positive C. diff is the leading cause of diarrhea amongst geriatrics.
124	Retrospective cohort study	To assess the impact of real-time notification upon detecting toxigenic C. diff	Single center. 433 bed tertiary care medical center. Lexington, Kentucky. Adult patients aged more than 18 years	Computer generated real-time notification of toxigenic C. diff results + Initiation of appropriate antimicrobial therapy (Vancomycin or Vancomycin + metronidazole). Contact precautions. Involved: Pharmacist led ASP team	The time for initiating appropriate treatment reduced from 5.75 to 2.05 hours. The ASP intervention shortened the time from diagnosis to recording the appropriate antimicrobial in the EMHRs	The real-time notification intervention reduced the time for entering and initiating the appropriate antimicrobial treatment as well as contact precautions.	
125	POS	To assess the impact of a multifaceted collaborative intervention on CDIs	Multisite 35 hospitals Hospitalized patients, 18+ years. US, NY	C. diff collaborative intervention: IP bundle: Contact precautions, signage, PPE, hand hygiene, isolation/cohorting. Environmental cleaning protocol Duration: 22 months Involved: Internal disciplinary team (Infection preventionist, physicians, nurses, support staff, and QI staff.)	95% mean compliance with IP bundles 96% mean compliance with environmental cleaning protocol. Reduction in HA-CDIs from about 13.5 to 8.5 per 10,000	The C. diff collaborative potentially impacts on hospital practices. The intervention has an effect on the other HAIs	

b. Klebsiella pneumoniae

Reference	Study type	Aims/ objectives	Population/ Setting	Intervention	Outcome/ key findings	Conclusions	Useful notes
-----------	------------	------------------	---------------------	--------------	-----------------------	-------------	--------------

126	ROS + POS Quasi-experimental Medical records	To devise a local strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant <i>Klebsiella pneumoniae</i> (CRKP)	CRKP patients 1000 bed tertiary care university hospital	ED flagging system Cohorting Eradicating clusters Environmental and personnel hand cultures Carbapenem restriction policy Duration: 36 months. Involved: Physicians, epidemiologists, nurses, infection control staff	CRKP infections reduced from 5.26 to 0.18 per 10,000 patient days No nosocomial CRKP infections diagnosed Meropenem use reduced		
127	Quasi-experimental?	To examine the effect of active screening on the resistance rates of MDRBs in ICUs	ICU. China	Active screening. Duration: 14 months	Improved detection of MDRBs (KP)	Active screening reduces the resistance rates of pathogenic bacteria and useful in detecting MDRB	
128	Quasi-experimental	To reduce the prevalence of CRKP (KPC-3)	Medical center Israel	Guidelines for isolation, cohorting, environmental cleaning, staff education, and computerized notification/ flagging Duration: 48 months. Involved: Consultants, nurses, IP staff, housekeeping staff, patients, and caregivers.	A decrease in the CRKP incidence rate sustained over 30 months from 6.6 to 0.5/10,000PDs Reduction in cross-infections from 6% to 2.7% Surveillance of asymptomatic carriers improved from 20% to 89%	A multidisciplinary IPC programme is effective in controlling the prevalence of CRKP	
129	Quasi-experimental	To optimize the use of antimicrobials	510-bed Danish university hospital Copenhagen University Hospital. Denmark	Multi-disciplinary change project Kotter's stages of change Multi-level intervention: 1. Professional: Education, clinician leaflets, new drug container, yellow sticker for bed post, signboard for doors, hotline, notification on prescription of restricted antimicrobials 2. Social: Presentations for the quality board, prevalence studies, feedback, newsletter and website. 3. Patient: Information leaflets for isolation precautions	Overall antimicrobials consumption remained unaffected. Immediate and sustained reduction in cefuroxime use (74.5%) An increase in the use of ertapenem, piperacillin/ tazobactam, and b-lactamase sensitive penicillin. Reduction in ESBL-KP diagnostic samples Reduced incidence of ESBL-KP infections from 39.5 to 22.5% Reduced need for isolation precautions	Changing antimicrobial consumption and reducing the incidence of ESBL-KP is possible through a multi-faceted intervention that does not require ongoing antibiotic stewardship	Restricting cephalosporins may reduce ESBL infection rates Carbapenems (B-lactamase inhibitors) are recommended as first-lines for serious ESBL producing bacteria

				<p>4. Organizational: Revising antimicrobial guidelines, cefuroxime restriction. Duration: 36 months.</p> <p>Involved: Physicians, nurses, pharmacy staff, and patients.</p>			
130	Quasi-experimental	To evaluate the impact of an AMS program restricting carbapenems (imipenem and meropenem)	<p>Hospital das Clinicas</p> <p>Institute of Orthopedics and Traumatology</p> <p>200 beds tertiary care hospital.</p> <p>Brazil</p>	<p>Antimicrobial restriction</p> <p>Ertapenem was made mandatory for treatment of ESBL-Enterobacteriaceae</p> <p>Restricting group 2 carbapenems for gram negative bacteria.</p> <p>Duration: 24 months.</p>	<p>A reduction of group 2 carbapenems use from 61.1 DDD to 48.7 DDD/1,000 patient days</p> <p>Susceptibility of K. pneumoniae and P. aeruginosa to trimethoprim-sulfamethoxazole</p>	There was a significant reduction in the use of carbapenems following preferential use of ertapenem.	
131	Prospective Observational study	To contain an outbreak of carbapenem resistant KP	<p>27 Acute care hospitals.</p> <p>14,000 beds.</p> <p>Israel</p>	<p>Screening</p> <p>Mandatory reporting of every CRE patient to PH authorities</p> <p>Mandatory isolation of hospitalized new and previous carriers (single rooms or cohorting)</p> <p>Dedicated staff</p> <p>Oversight taskforce that supervised adherence to isolation protocols, provided technical support, and feedback to management.</p> <p>Duration: 14 months.</p> <p>Involved: Nurses, IP staff, microbiologists, laboratory staff, physicians, and Public health staff</p>	Increase in the incidence of KP was halted with a subsequent reduction of 11.7 cases per 100,000	An intervention coordinated centrally showed better outcomes for containment of a KP outbreak as compared to local measures. Strategic planning and national oversight are crucial in addressing AMR	Outbreak control
132	Outbreak investigation	To curb the spread of KPC-3 producing KP	<p>Italy</p> <p>12-bed ICU hospital</p> <p>Cannizaro hospital, Catania</p>	<p>Screening</p> <p>Environmental cleaning</p> <p>Respiratory equipment disinfection</p> <p>Hand hygiene</p> <p>Single room isolation</p>	<p>Outbreak containment within 4 months</p> <p>Improved adherence to contact precautions</p>		<p>Outbreak control</p> <p>Ten recognized KPC types (KPC-2 to KPC 11). KPC-2 are the commonest</p>

				<p>Weekly meetings between IPTs and ICU staff.</p> <p>Duration: 2 months.</p> <p>Involved: Nurses, ICU staff, IP staff, and cleaning staff.</p>			
133	POS	To curb CRKP and Acinetobacter baumannii	<p>Serres General Hospital</p> <p>250-bed hospital</p> <p>Greece</p>	<p>Prokroustes action plan:</p> <p>Surveillance and compulsory notification + IPC measures: Isolation or cohorting, contact precautions, hand hygiene</p> <p>Duration: 36 months</p>	<p>Containment of CR associated with KP and PA three years post-intervention.</p> <p>An increase in KP resistant to Colistin, Tigecycline, and gentamycin</p>	There exist challenges for addressing MDROs in regions with established carbapenem resistance.	
134	Observational	To identify and control CRKP originating from endoscopic equipment	<p>206-beds cancer center + 988 beds tertiary hospital.</p> <p>Florida, USA.</p>	<p>Active surveillance using rectal swabs</p> <p>Source isolation</p> <p>Contact precautions</p> <p>Environmental cleaning</p> <p>Hand hygiene</p> <p>PPE: Gowns + gloves</p> <p>MDRO flags on EMRs and charts</p> <p>Duration: 6 months.</p> <p>Involved: Epidemiologists and health personnel</p>	7 CRKP cases identified resistant to imipenem		<p>Transmission of carbapenem resistant genes across microbial spp within the same environment contributes to resistance.</p> <p>KP outbreaks have also been associated with contaminated sinks, IV saline solutions, bath soap, and ultrasonography gel</p>
135	Quasi-experimental	To assess the impact of intensified IC measures on colonization and infections associated with CRKP, P. aeruginosa, and Acinetobacter baumannii	<p>Hippokraton General Hospital.</p> <p>Solid organ transplant department.</p> <p>Thessaloniki, Greece</p>	<p>Active surveillance, contact precautions, hand hygiene, education, environmental cleaning, monitoring adherence, audit and feedback.</p> <p>Duration: 17 months.</p> <p>Involved: Nurses, doctors, non-surgical staff.</p>	<p>Reduction in incidence of colonization from 19 to 9%.</p> <p>Improved adherence to contact precautions.</p> <p>An increase in the monthly incidence of CR bacteria from 2.8 to 6.9/ 1000 PDs</p>	In CR gram -ve bacteria endemic regions, SOT patients have disproportionately higher infections rates of the organisms. Implementation of enhanced IC measures significantly	

						reduces the colonization	
136	POS	To control an outbreak of imipenem resistant <i>K. pneumoniae</i> (IR-KP)	Abdominal surgery care center. 15-bed liver ICU. France	Screening all patients + Contact isolation + hand hygiene using alcohol-based hand sanitizer. Enhanced measures: Cohorting carriers, dedicated staff, restricting ward admissions, and strict control of patient transfers. Duration: 4 months. Involved: Nurses, medical staff, physicians, and microbiologists.	Rapid containment of the outbreak		
137	Quasi-experimental	To establish if IPC interventions can reduce CRKP infection in ICU	ICU China 629 patients enrolled.	Screening of cultures, de-escalation interventions, contact precautions, isolation/ cohorting, sterilization and disinfection, and bundles (for IV catheter infections, VAP, CAUTIs, and skin or soft tissue infections). Duration: 24 months Involved: Consultants, physicians, nurses, ID specialists	CRKP incidence reduced from 10.08 to a low of 2.84 cases per 1000 PDs. ICU acquired CRKP bloodstream infections decreased from 2.54 to 0.41 cases per 1000PDs	Comprehensive IPC interventions significantly reduced ICU related CRKP infections	
138	Quasi-experimental	To assess the effect of IPC on a CRKP outbreak	NICU. 20-beds. 8 patients. China	Active surveillance using rectal swabs. IPC measures: hand hygiene, auditing compliance, environmental cleaning, and cohorting. Duration: 8 months Involved: Nurses and IP professionals	Outbreak containment after cohorting and IPC measures.	Physical isolation is important in preventing the spread of MDROs. ASP is useful in reducing the spread of MDROs	
139	Cohort. POS	Assessing the effectiveness of multidisciplinary interventions on the transmission of ESBL-KP	Parkland Memorial Hospital. NICU. 61 infants. Dallas, USA	Re-educating staff. Auditing hand hygiene and environmental sanitation. Contact precautions. Cohorting Staff & infants. Reducing overcrowding. Screening NICU cultures frequently.	Outbreak contained within three weeks	Multidisciplinary intervention using standard IPC measures halted the transmission of ESBL-KP in the NICU.	

				<p>Duration: 3 weeks.</p> <p>Involved: Neonatologists, ID physicians, nurses, managers, epidemiologists, respiratory therapists, microbiologists, IP staff, and environmental officers.</p>			
140	POS	To halt the spread of CRKP	<p>Cà Granda Ospedale Maggiore Hospital.</p> <p>ICU.</p> <p>Milan, Italy</p>	<p>Active surveillance.</p> <p>Isolation.</p> <p>Hand hygiene.</p> <p>Duration: 2 months.</p> <p>Involved: Healthcare workers.</p>	Outbreak containment		
141	ROS & POS	To assess the effect of enhanced contact precautions on CRE/CRKP incidence and resistance rates	<p>Tertiary care university hospital.</p> <p>900 beds.</p> <p>South Korea</p>	<p>Staff education</p> <p>Contact precautions without active surveillance.</p> <p>Cohort isolation.</p> <p>Hand hygiene.</p> <p>Duration: 26 years</p> <p>Involved: physicians and medical personnel</p>	<p>An initial increase of the CRE cases (from 1.62 to 9.81/100,000PDs) after which the rates fell back to (0.882/100,000PDs) below baseline levels.</p> <p>A reduction in the resistance rates to imipenem and meropenem following enhanced contact precautions.</p> <p>Hand hygiene adherence improved from 35.2% to 70%</p>	Enhanced infection control measures without active surveillance appear to be effective against the spread of CRE in low prevalence settings	
142	ROS & POS	To stop the spread of ESBL-producing nosocomial bacteria in NICU	<p>17-bed NICU.</p> <p>355 patients observed.</p> <p>University of Szeged Pediatrics Department.</p> <p>Hungary</p>	<p>Introduction of the INSURE protocol.</p> <p>Antimicrobial regimens review.</p> <p>Microbiological screening.</p> <p>Bathing protocol.</p> <p>Hand hygiene.</p> <p>Continuous monitoring of cases.</p> <p>Duration: 3 months.</p> <p>Involved: Nurses, clinicians, cleaning staff, all staff.</p>	<p>A significant reduction in the proportion of CRKP colonization or infections.</p> <p>Average number of PDs reduced from 343.72 to 292.44 PDs/ month.</p> <p>Hand hygiene compliance improved from 26.02 to 33.6 HH procedures per patient per hospital day.</p>	A successful roll back of the CRE infections and colonization was achieved through an interdisciplinary approach.	ESBL-producing bacteria includes E. coli, Enterobacteriaceae, and KP

143	Quasi-experimental	To track an outbreak of ESBL-KP using WGS	The University Medical Center Groningen (UMCG). 1300 bed tertiary care center. Netherlands	Screening patients and the environment using WGS. Duration: 6 months. Involved: Nurses, physicians, respiratory therapists, housekeepers, and visitors.	There was no association between the sporadic case of KP and those that had been diagnosed prior to 2013	Tailor-made makers for identifying genomic signatures have potential for improving the efficiency of IPC measures	
-----	--------------------	---	--	---	--	---	--